Unknown PHASE2 INTERVENTIONAL 1-arm NCT05122091

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

A Single-arm, Multicenter, Open-label Phase II Study of Fruquintinib Plus SOX as a Neoadjuvant Therapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Sponsor: Guangxi Medical University

Conditions Fruquintinib Gastric Cancer GastroEsophageal Cancer SOX

Interventions Fruquintinib + SOX

Updated 6 times since 2021 Last updated: Feb 22, 2024 Started: Nov 5, 2021 Primary completion: Nov 5, 2024 Completion: Nov 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05122091, this PHASE2 trial focuses on Fruquintinib and Gastric Cancer and remains ongoing. Sponsored by Guangxi Medical University, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Mar 2026 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Jan 2023 — Mar 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Dec 2021 — Jan 2023 [monthly]

Recruiting PHASE2

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangxi Medical University

Data source: Guangxi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanning, China